Sanuwave Announces Q3 FY2026 Financial Results
SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio
How this was made
The 30-second read
Why it matters
The earnings miss may trigger short‑term sell‑offs, but longer‑term outlook depends on CMS policy evolution and hospital adoption.
Market read
Micro‑cap earnings miss with negative guidance; likely short‑term downside for SNWV.
What to watch
One‑time gains from patent sales and derivative adjustments in prior year inflate the prior profit, making the decline appear larger.
Background
Sanuwave Health, a Nasdaq‑listed wound‑care device maker, filed its 8‑K earnings release for Q3 FY2026.
Ticker impact
Q3 FY2026 results show revenue down 24% and a swing to a $1.1M operating loss, marking a material earnings miss.
downward pressure as investors price in weaker revenue and loss
Revenue decline and loss reversal are fresh, material data for a micro‑cap; no mitigating guidance was provided.
Market effects
Wound‑care device sector may see broader scrutiny as the CMS rule impact is highlighted.
Limited to U.S. healthcare investors; no broader regional effect.
Low global relevance beyond niche medical device niche.
Counterpoint
If the CMS rule changes later in 2027 improve reimbursement, the current loss could be a buying opportunity.
Key entities
- CEOMorgan Frank
Commented on CMS rule impact and future opportunities.
